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Poster Session II S333between the groups except a higher percentage of normal cytogenet-
ics in patients with FLT3/ITD+ (p 5 0.025).Two year OS, DFS,
non-relapse mortality (NRM), and relapse of cohort were 60.8%,
55.8%, 18.0% and 31.3%, respectively. Univariate analysis showed
FLT3/ITD+ compared to FLT3/ITD- patients was significantly as-
sociated with inferior DFS (2 year DFS: 19% vs. 64%, p\0.0027),
increased risk of relapse (1 year: 59%vs. 19%, p\0.0009), and a trend
towards decreased OS (p 5 0.08). 5 of the 16 FLT3/ITD+ patients
were also positive for NPM1, which did not impact outcome. Mul-
tivariate analysis using the Cox proportion hazard regression model
confirmed that FLT3/ITD+ mutations independently predicted
a shorter DFS (hazard ratio [HR], 3.0; 95% CI, 1.4-6.5; p 5
0.004) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3,
p 5 0.001). Time to relapse in patients with FLT3/ITD+ was very
short with 100 days cumulative risk of 45%.
Conclusion:Our data suggests that allo-SCT in FLT3/ITD+ AML
CR1 does not appear to overcome the poor prognostic value, and
these patients remain at high risk of early relapse even after allo-
SCT.While our study is limited by small size, this further illustrates
the urgent need for larger prospective studies to validate the efficacy
of allo-SCT in CR1 and the need to design therapy targeting FLT3/
ITD either prior to or early-post transplant to decrease relapse for
this specific subgroup.347
THIOTEPA (Tt), BUSULFAN (Bu), AND CLOFARABINE (Clo) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: UP-
DATED RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kelly, S.S.1, Petropoulos, D.1, Lee, D.A.1,
Kebriaei, P.2, Cooper, L.J.N.1, Champlin, R.E.2 1M D Anderson Cancer
Center, Houston, TX; 2M D Anderson Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) is a well-tolerated
conditioning regimen for allo HSCT. New nucleoside antimetabo-
lites are available with the potential for improved anti-tumor effect.
We substituted Clofarabine (Clo) for F for its better antileukemic ac-
tivity. To address the blood-brain barrier we added Thiotepa (Th),
a polyfunctional alkylating agent. These data report on combining
the Th + (IV)Bu + Clo in a conditioning regimen for high risk pa-
tients.
Patients and Methods: 31 patients received Th 5 mg/kg over 1 hr.
Bu was administered x 3 days over 3 hr to a daily AUC of 5,000
mcMol-min +/-10%. Clo 40mg/m2 was infused over 1 hr daily x 4
days. 29 patients are evaluable for engraftment and survival beyond
day + 30. M/F: 18/13. Median age 18 y (range 2-60). 16 patients
had AML [IF (2), relapse refractory (4), relapse untx(3), CR2 (6),
. CR2 (1)]. 14 patients had ALL [CR1 (1), CR2 (4), CR3 (5), Re-
lapse sensitive (2), relapse resistant (1) relapse untx(1)]. One patient
had CML ($ 3 CP). 7 had received prior transplants this being their
2nd (4), 3rd (2), 4th (1)]. GVHDprophylaxis was tacrolimus andmini-
MTX or tacrolimus and MMF (CB recipients). Those with one
Ag-mism or unrelated grafts received rabbit-ATG. Stem cell sources
included cord (17); MUD-apheresis (4), MUD-BM (5), MSD–
apheresis (4) MSD-BM (1).
Results: 15 patients are alive although 3 have relapsed (d132, d139,
d231) for a median OS 320 d (120-833). Common regimen-related
toxicities were GI and esophagitis. Self-limited hemorrhagic cystitis
due to BK virus occurred in 7 patients. Deaths from VOD/Pulmo-
nary hemorrhage (4) occurred in patients receiving Gemtuzumab
Ozogamicin or Inotuzumab ozogamicin therapy. Acute GVHD oc-
curred in  50% of all patients Grade II-IV (7). None (12) NE (4).
Chronic GVHD occurred in 5 patients, none (19), NE (7). Deaths
(16) were due to relapse (9) PFS 90 d (30-279), late infection (1)
d 259. The other 6 patients who died all received ozogamicin ther-
apy. PB microsatellite chimerism at day +30 showed 100% donor
T cell and myeloid cells in all but 4 patients who went on to relapse.
Conclusion: This regimen is overall safe unless administered after
recent ozogamicin therapy. Significantly, patients with refractory
disease at the time of HSCT achieved a CR. Engraftment in recipi-
ents of UCB transplants was robust (medium 18 days). In aggregate,
this chemotherapy regimen provided an anti-leukemia effect and
warrants further investigation.348
ADOPTIVE IMMUNOTHERAPY USING ANTI-THYMOCYTE GLOBULIN AND
REDUCED INTENSITY TOTAL BODY IRRADIATION; A COST-EFFECTIVE
STRATEGY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
Shickle, L.M.2, Hazlett, A.F.1, Jin, Y.2, Sabo, R.T.1, Korshin, T.2,
Chung, H.M.1, McCarty, J.M.1, Clark, W.B.1, Toor, A.A.1,
Roberts, C.H.1 1VCU Massey Cancer Center, Richmond, VA; 2VCU
Massey Cancer Center, Richmond, VA
Allogeneic stem cell transplants (SCT) conditioned with conven-
tional regimens continue to be fraughtwith complications, increasing
resource utilization and downstream costs associated with these
procedures. We have developed an investigational conditioning reg-
imen, incorporating anti-thymocyte globulin (ATG; Thymoglobu-
lin, Sanofi-Aventis) and reduced-intensity total body irradiation,
with the goal of reducing complications following SCT
(NCT00709592). To determine the cost savings associated with
the use of this regimen, we performed a retrospective analysis of di-
rect costs incurred during the first 100 days following SCT.We com-
pared the investigational group of patients (IG; n5 25) with a control
group transplantedduring the same timeperiodand conditionedwith
either reduced intensity busulfan ormelphalan + fludarabine contain-
ing regimens (CG; n5 32). The IG and CG differed in age (57 vs. 53
years; F-Test, p5 0.04), number of prior regimens (4 vs. 2; p\0.01),
and disease distribution (p\0.001), but had a similar proportion of
matched related and unrelated donors (p 5 0.12). At a median fol-
low-up of 20months in the IG and 12months in the CG, the survival
in the two groups is similar (one-year K-M survival estimate 73% vs.
53%, Log Rank p 5 0.16). Inpatient hospitalization following SCT
was shorter for IG, 17 (67) days, compared to the CG, 24 (616)
days (p 5 0.02). Direct cost incurred during the study period was
lower for the IG ($121,103 6 47,292) compared to the CG
($194,392 6 93,760) (p\0.01), this despite the entire IG surviving
to day 100 (4 deaths in the CG). When patients who relapsed or
died during this period were excluded from analysis the cost differ-
ence remained in favor of the IG, $118,546 6 48,567 vs. $188,239
6 92,484 for the CG (p\0.01). Table 1 displays the trends in the
cost incurred over time for the investigational and control groups.
The cost savings spanned a variety of categories, including pharma-
ceutical, blood bank, laboratory and inpatient charges. We conclude
that despite being heavily pretreated, patients conditioned with the
investigational ATG + TBI regimen spent fewer days in the hospital
and had a lower cost associated with transplantation. Given the cur-
rent economic climate, our findings suggest that rethinking conven-
tional methods of reduced-intensity conditioning, with emphasis on
adoptive immunotherapy rather than dose intensity,may improve the
cost-effectiveness of allogeneic SCT.
Table 1. Total and InpatientCostsUpToDay100FollowingSCT
Time Period Control Group Investigational Group p ValueTotal Costs
1-100 Days $194,392 $121,103 <0.01
1-30 Days $70,750 $49,306 <0.01
31-60 Days $30,216 $16,028 <0.01
61-100 Days $37,841 $16,709 0.05
Inpatient Costs
1-100 Days $51,442 $36,084 0.04
1-30 Days $26,266 $21,411 0.06
31-60 Days $7,732 $1,706 0.02
61-100 Days $11,972 $2,008 0.04The costs are mean values and standardized to FY 2012 $. The p-value
was calculated using analysis of variance (F test).
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ENCOURAGING SURVIVAL FOR PATIENTS WHO HAD A SECOND UMBILI-
CAL CORD BLOOD TRANSPLANT FOR GRAFT FAILURE
Lund, T.C.1, Verneris, M.R.1, Tolar, J.1, Cao, Q.2, Weisdorf, D.J.2,
Wagner, J.E.2, Brunstein, C.G.2 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
After umbilical cord blood transplantation (UCBT), the 10-15%
risk of graft failure (GF) remains a significant source or morbidity
